Technology Platforms

Oral Solid Dosage Forms

Our modified release solid dosage forms are based on matrix, film coating, pellet/bead coating, gastric retention, pusatile, mucosal, and osmotic pump technologies. We utilize these technologies to develop difficult to formulate generic products as well as 505 b 2 NDA products to extend life cycle of aging drugs currently on the market.

Our solid dosage forms for water insoluble drug candidates are based on solubility/bioavailability enhancing technologies such as complexation, solid dispersion, micellization, liposome, self-emulsifying, and particle size reduction technologies.

Our solid dosage forms for unstable drug candidates are based on drug entrapment, drug isolation, layering, and pH control stabilization technologies.

Oral Liquid Dosage Forms

Our modified release liquid oral dosage forms such as oral solutions, emulsion, & suspensions are based on cyclodextrin, micellization, lipid, SEDDS, & multi-particulate matrix & film coating technologies.

Parenteral Dosage Forms

Our modified release injectable dosage forms for chemical drugs & biologics are based on our multiparticular, implantable drug delivery, and liposomal technologies. Our modified release injectable technologies are suitable for drugs with short eliminating half-life, especially for proteins and peptides. Our intra-muscular injectable suspension systems are particularly suitable for cancer, drug abuse, & anti-psychotic treatments where a less frequent injection schedule is much preferred for improved patient compliance.

Transdermal Patch Systems

Our transdermal drug delivery systems are based on our matrix type transdermal technology which does not carry the risk of dose dumping of the reservoir type technology. Our transdermal drug delivery systems are suitable for drugs indicated for pain management, Alzheimer, & drug abuse treatments.